Titre
Clinical pharmacology of ACE inhibition
Type
synthèse (review)
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Nussberger, J.
Auteure/Auteur
Waeber, B.
Auteure/Auteur
Brunner, H. R.
Auteure/Auteur
Liens vers les personnes
Liens vers les unités
ISSN
0008-6312
Statut éditorial
Publié
Date de publication
1989
Volume
76 Suppl 2
Première page
11
Dernière page/numéro d’article
22
Notes
Journal Article
Review
Review
Résumé
The radioimmunological determinations of immunoreactive 'angiotensin II' do not truly reflect angiotensin-(1-8)octapeptide levels, and thus cannot provide an accurate reflection of the efficacy of angiotensin-converting enzyme (ACE) inhibition. Elaborate methods are necessary to measure specifically the octapeptide angiotensin II. This methodology confirms that ACE inhibitors reduce circulating angiotensin II and that tolerance to the angiotensin II-lowering effect of ACE inhibitors does not develop, even after prolonged administration. Furthermore, a marked reduction of angiotensin II levels can be shown even in patients with primary aldosteronism. At peak blockade of ACE, the level of plasma angiotensin II is still related to circulating active renin and angiotensin I. The possible independent role of tissue renin-angiotensin systems in determining vasomotor tone is an interesting hypothesis. However, any discussion of whether tissue or plasma renin determines the pharmacologic effect of ACE inhibitors should be based on the simultaneous measurement of angiotensin-(1-8)octapeptide under steady-state conditions in tissue and plasma.
Sujets
PID Serval
serval:BIB_EA69AB59D9C3
PMID
Date de création
2008-03-05T15:40:31.979Z
Date de création dans IRIS
2025-05-21T05:10:30Z